New paper show fluorescent light energy enhances post mastectomy wound healing in dogs
Managing surgical wound following mastectomy in female dogs can be challenging, with issues such as poor wound healing and post-operative infection often hindering recovery. Peri-operative antibiotics are sometimes prescribed to mitigate these risks. However, a groundbreaking study offers promising results for the use of fluorescent light energy (FLE) in the management of post-operative wounds, revealing improved quality of wound healing, reduced infection risk and a lower home care burden for owners.1 The full study can be read here: https://bit.ly/phoviaFLE
Led by Dr. Andrea Marchegiani, the study investigated the efficacy of a two-part FLE system (Phovia®, Vetoquinol) in nine female dogs that had undergone unilateral or bilateral mastectomy for mammary neoplasia. In each dog, half of the wound was managed with FLE, while the remaining half served as the control and received no FLE.
All wound portions managed with FLE showed improved wound healing as assessed by scoring of four parameters: apposition of wound edges, skin contour irregularity, separation of wound margins and scar distortion. Moreover, when taking into account inflammatory indexes such as erythema, edema, and serous discharge, these were significantly lower for those wound portions managed with FLE.
To assess the potential benefits of FLE in reducing infection risk, swabs were taken for culture and sensitivity three, five and seven days after surgery. The swabs from all FLE-managed wound portions showed no bacterial growth, in contrast to the control wounds, in which three dogs had positive culture results.
Reflecting on the significance of these findings, Dr. Marchegiani says, “For many reasons healing of surgical wounds can become challenging, especially after removal of mammary gland lumps. Veterinary clinicians have to face the three-fold challenge of meeting owner expectations of prompt and trouble-free wound healing, recognizing those wounds in which healing may be prolonged or impaired and also following the principles of antibiotic stewardship.”
Phovia is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp. When used together they produce light of varying wavelengths that penetrates the skin to different depths, helping to control bacteria and reduce inflammation on the surface of the skin and stimulating regeneration in the epidermal and dermal layers. The unit is portable, and applications take only four minutes once a week. After diagnosis and subsequent recommendation by a licensed veterinarian, any trained member of the clinical team can use Phovia.
The results of the study underscore the positive impact of FLE on the healing of post-mastectomy wounds in female dogs, offering the dual benefits of reducing potential infection risks and with a reduced risk of post-operative complications, a lessened home care burden for pet owners.
For further information visit https://www.vetoquinolusa.com/products/phovia-fluorescent-light-therapy-system email usa_news@vetoquinol.com or read the full paper here: https://bit.ly/phoviaFLE
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the farm animals (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group’s hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high-potential growth markets. It employs around 2,500 people.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.
ABOUT PHOVIA™
Distributed by Vetoquinol, the innovative PHOVIA is a non-invasive light system based on Fluorescent Light Energy (FLE) therapeutic approach. PHOVIA supports the tissue regeneration and contributes to accelerate the healing process by acting through multiple mechanisms at the cellular and molecular levels (FLE has been shown to attenuate the inflammation, accelerate fibroblast proliferation, enhance collagen synthesis, and modulate angiogenesis). When used in accordance with the product information, PHOVIA is painless, safe, easy and a quick procedure empowering the clinic staff to provide advanced care. With proven expedited recovery, either used alone or combined with antibiotics and/or standard of care, PHOVIA can accelerate healing in numerous skin conditions and traumatic/surgical injuries up to two-fold compared to standard of care alone,2,3,4 thereby increasing the quality of life of pets and their caregivers.5 By reducing the need for the use of antibiotics, PHOVIA contributes to the prudent and responsible use of antimicrobials as an alternative or support to conventional treatment standards.
Media contact: Jennifer Ryan, usa_news@vetoquinol.com
References:
1 Marchegiani, A.; Troisi, A.; Bazzano, M.; Spaterna, A.; Fruganti, A. A prospective, blinded, open-label clinical trial to assess the ability of Fluorescent Light Energy to enhance wound healing after mastectomy in female dogs. Animals 2024, 14, 1250. https://doi.org/10.3390/ ani14081250
2 Marchegiani A, Spaterna A, Cerquetella M. Current Applications and Future Perspectives of Fluorescence Light Energy Biomodulation in Veterinary Medicine. Vet Sci. 2021 Jan 25;8(2):20.
3 Marchegiani A, Spaterna A, Fruganti A, Cerquetella M. Exploring fluorescent light energy as management option for canine superficial bacterial folliculitis. Front Vet Sci. 2023 Jun 2;10:1155105.
4 Marchegiani A, Spaterna A, Cerquetella M, Tambella AM, Fruganti A, Paterson S. Fluorescence biomodulation in the management of canine interdigital pyoderma cases: a prospective, single-blinded, randomized and controlled clinical study. Vet Dermatol. 2019 Oct;30(5):371.
5 Mosca M, Briand A, Carrasco I, Luciani L, Fantini O. Impact of Fluorescent Light Energy on the Quality of Life of Dogs with Dermatologic Disease and Their Owners. Open Journal of Veterinary Medicine. 2023;13:122-135.
©2024 Vetoquinol USA, Inc. Vetoquinol and Phovia are trademarks of Vetoquinol. Phovia is manufactured by Klox Technologies and distributed by Vetoquinol USA under license from Klox Technologies.
Latest news
FDA Approves Extended Expiration Date for Clevor® (ropinirole ophthalmic solution)
August 2024
UpCard®-CA1 (torsemide oral solution) is Now Available
July 2024
UpCard®-CA1 (torsemide oral solution) from Vetoquinol Receives Conditional Approval
May 2024